Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04548648 · OUTCOME

Duration of Response (DoR)

A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas · Source last updated 2026-06-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
days
Interval / dispersion
Not reported
Time frame
2 years

What was measured

Duration of response (DoR) is defined as time from documentation of tumor response to disease progression according to the International Primary CNS Lymphoma Collaborative Group response assessment criteria.

Analysis population: Participants who achieved a complete response were included.

Groups in this outcome

Open-label, Single-arm

Subjects with relapsed primary central nervous system lymphoma (PCNSL) or relapsed secondary CNS lymphoma (SCNSL) without systemic disease will receive acalabrutinib until disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Open-label, Single-arm1

Reported measurements

Source class 1
Values in days · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Open-label, Single-arm341Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        341
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    units
    Participants
description
Duration of response (DoR) is defined as time from documentation of tumor response to disease progression according to the International Primary CNS Lymphoma Collaborative Group response assessment criteria.
groups
  1. description
    Subjects with relapsed primary central nervous system lymphoma (PCNSL) or relapsed secondary CNS lymphoma (SCNSL) without systemic disease will receive acalabrutinib until disease progression or unacceptable toxicity.
    id
    OG000
    title
    Open-label, Single-arm
param Type
NUMBER
population Description
Participants who achieved a complete response were included.
reporting Status
POSTED
time Frame
2 years
title
Duration of Response (DoR)
type
SECONDARY
unit Of Measure
days

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice